Pipeline Collaboration
Collaboration opportunities for clinical development, registration, and commercial authorization of existing pipelines including recombinant influenza vaccine and COVID-19-influenza combination vaccine.
Innovative Vaccine Pipelines | Recombinant Influenza Vaccine & COVID-19-Influenza Combination Vaccine
- Recombinant Influenza Vaccine: The first trivalent influenza vaccine in China developed using insect cell-expressed recombinant proteins, compliant with WHO's latest recommendations. It demonstrates excellent safety and broad applicability (suitable even for egg-allergic individuals). In populations aged above 50, this recombinant vaccine shows over 30% superior efficacy compared to traditional egg-based split vaccines. The IND application is currently in progress.
- COVID-19-Influenza Combination Vaccine: No globally approved COVID-19-flu combination vaccine exists yet. As China's only company with mature insect cell expression platforms for both COVID-19 and influenza vaccine production, this combination vaccine is poised to become China's fastest-developed combination vaccine, with planned IND submission in the near term.
Guided by our philosophy "We Initiate Science & Technology Value, Always for Caring", WestVac Biopharma is committed to delivering safe, effective, and accessible vaccine products through internationally advanced insect cell technology platforms, contributing to global public health security.
